[AsCNP_P23] ポスター23
Schizophrenia 2

[AsCNP-P23-3] Efficacy and Safety of Lurasidone in Acutely Psychotic Patients with Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (JEWEL Study)

^○Kentaro TAKAI¹, Masaomi IYO², Jun ISHIGOOKA³, Masatoshi NAKAMURA¹, Reiko SAKAGUCHI¹, Keisuke OKAMOTO¹, Teruhiko HIGUCHI^{4, 5} (1. Sumitomo Dainippon Pharma Co., Ltd., Japan, 2. Chiba University Graduate School of Medicine, Japan, 3. Institute of CNS Pharmacology, Japan, 4. Japan Depression Center, Japan, 5. The National Center of Neurology and Psychiatry, Japan)